Europe
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 22, 2020.
AstraZeneca’s COVID-19 vaccine candidate induced significant immune responses in the majority of patients following a single dose in a Phase I study. The preventative medication also proved to be fairly safe, study results showed.
Sanofi is lining up to spin off its active pharmaceutical ingredients division that will include a listing as a public company, Reuters reported, citing unnamed sources.
No financial terms were disclosed, but they are apparently based on delivery time and dose volume.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 20, 2020.
The two companies will combine their mRNA research to develop the potential vaccines across a range of infectious disease pathogens.
Company shares exploded 373% at the news.
Wrapping up the month of July, there are three PDUFA dates on the U.S. Food and Drug Administration (FDA) calendar.
It was a surprisingly big week for clinical trial updates related to COVID-19, although there was plenty of non-COVID-19 news as well. Here’s a look.
Rumors are flying that Paris-based Sanofi has a $50 billion budget for mergers and acquisitions and is taking a look at U.S.-based biotech companies. At the top of the list, reportedly, is South San Francisco-based Principia Biopharma.
PRESS RELEASES